Psychosocial interventions for reducing diabetes distress in vulnerable people with type 2 diabetes mellitus
Mathiesen, Anne Sophie; Egerod, Ingrid; Jensen, Tonny; Kaldan, Gudrun; Langberg, Henning; Thomsen, Thordis

Published in:
Diabetes, Metabolic Syndrome and Obesity

DOI:
10.2147/DMSO.S179301

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Psychosocial interventions for reducing diabetes distress in vulnerable people with type 2 diabetes mellitus: a systematic review and meta-analysis

Anne Sophie Mathiesen1
Ingrid Egerod2
Tonny Jensen1
Gudrun Kaldan3
Henning Langberg4
Thorids Thomsen3

1Department of Endocrinology, Abdominal Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 2Intensive Care Unit 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 3Abdominal Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 4CopenRehab, Section of Social Medicine, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Abstract: Diabetes distress (DD) disproportionately affects vulnerable people with type 2 diabetes mellitus and interventions targeting this population are therefore relevant. A systematic review and meta-analysis was performed to assess the evidence for an effect of psychosocial interventions for reducing DD, and, secondly HbA1c, depression, and health-related quality of life in vulnerable people with type 2 diabetes mellitus. Vulnerability encompasses poor glycemic control (HbA1c > 7.5%) and at least one additional risk factor for poor diabetes outcomes such as low educational level, comorbidity, and risky lifestyle behavior. The interventions should be theoretically founded and include cognition- or emotion-focused elements. We systematically searched four databases for articles published between January 1995 and March 2018. Eighteen studies testing a variety of psychosocial interventions in 4,066 patients were included. We adhered to the Cochrane methodology and PRISMA guidelines. Review Manager 5.3 was used for data extraction and risk of bias assessment, and Grades of Recommendation, Assessment, Development and Evaluation for assessing the quality of the evidence. Data were pooled using the fixed or random effects method as appropriate. We investigated effects of individual vs group, intensive vs brief interventions, and interventions with and without motivational interviewing in subgroup analyses. To assess the robustness of effect estimates, sensitivity analyses excluding studies with high risk of bias and attrition > 20% were conducted. We found low to moderate quality evidence for a significant small effect of psychosocial interventions on DD, and very low to moderate quality evidence for no effect on HbA1c, both outcomes assessed at 3, 6, 12, and 24 months follow-up. The effect on depression was small, while there was no effect on health-related quality of life. Exploratory subgroup analyses suggested that interventions using motivational interviewing and individual interventions were associated with incremental effects on DD. Likewise, intensive interventions were associated with significant reductions in both DD and HbA1c.

Keywords: diabetes distress, HbA1c, meta-analysis, psychosocial interventions, type 2 diabetes, vulnerable populations

Introduction
The daily demands of people living with type 2 diabetes mellitus (T2DM) may increase the risk of diabetes distress (DD).1 DD is a condition of stressful feelings associated with the challenges of managing diabetes and concerns related to diabetic complications.1 The prevalence of DD ranges from 18% to 35% in a general population with T2DM,2,3 but is substantially higher in ethnic minority subgroups and in hospitalized patients.4 DD is associated with a longer duration of diabetes diagnosis, reduced adherence to treatment5 and glycemic control6 leading to an
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy downloaded from https://www.dovepress.com/ by 130.225.98.216 on 10-Jan-2019
For personal use only.

Mathiesen et al

1 / 1

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12

Objective

To examine the evidence for an effect of psychosocial interventions vs standard care for reducing DD and HbA1c, depression, and health-related quality of life (HRQOL) in vulnerable people with T2DM.

Materials and methods

This is a systematic review adhering to Cochrane methodology. The review was registered in PROSPERO (The International Prospective Register of Systematic Reviews) with registration number CRD42018064454 and reported according to the PRISMA guidelines.24

Types of studies

We included parallel group randomized clinical trials (RCTs) assessing DD as either a primary or secondary outcome. Exclusion criteria were as follows: cluster-randomized trials due to the potential lack of sensitivity to individual vulnerability characteristics,25 cross-over randomized trials, and nonrandomized controlled trials.

Participants

Participants were vulnerable people with type 2 diabetes duration for more than 1 year, ≥18 years, and HbA1c >7.5% (58 mmol/mol) at baseline. Vulnerability was defined as in the included studies, but including at least one or more of the following criteria: low socioeconomic status, low health literacy, Hispanic, African-American or other ethnic origin predisposed to an elevated risk of T2DM,26 comorbidity, or risky lifestyle defined as body mass index >30, sedentary lifestyle, smoking, or alcohol use exceeding 7 units weekly for women and 14 units weekly for men. The vulnerability criteria were informed by recommendations in the PROGRESS27 PLUS framework, which is an “equity lens” also applied by the Cochrane Collaboration. The PLUS edition includes individual characteristics such as lifestyle behaviors. We excluded studies including both type 2 and type 1 diabetes as no socioeconomic gradient has been described in type 1 diabetes.28

Types of interventions

Psychosocial interventions that were emotion focused and/or cognition focused and administered person-to-person, in groups, or digitally, by peers, caregivers or health care professionals, either alone or in combination, for reducing DD in vulnerable people with T2DM. Emotion-focused interventions aim to address patients’ self-management practices and thereby influence health outcomes,29 while cognition-focused interventions involve education and acquisition of diabetes-related skill training. The theoretical foundations underlying interventions should be prespecified in the methods section.
or study protocol. Included interventions could be brief or intensive and delivered in health care or homecare settings.

Controls
Usual care as defined in included studies. If studies had more than one arm, the arm most similar to usual care was selected as the control.

Outcomes
Primary outcome
DD assessed by Problem Areas in Diabetes (PAID) or the Diabetes Distress Scale (DDS) at 3, 6, 12, and 24 months. In DDS, mean item scores of 2.0–2.9 indicate moderate distress, and scores >3 indicate clinically important distress requiring intervention. For the validated 20-item PAID scale, scores >40 indicate clinically important distress.

Secondary outcomes
HbA1c measured at 3, 6, 12, and 24 months follow-up. For studies where follow-up time points did not match exactly, data from the closest time point were included. Depression was measured with validated instruments such as Patient Health Questionnaire (PHQ-9) at the longest follow-up. HRQOL was measured with validated instruments or diabetes-specific instruments such as Diabetes Quality of Life at the longest follow-up.

Search strategy
We searched PubMed/Medline, EMBASE, CINAHL, and PsycINFO using different combinations in a search matrix based on the PICO (patient, intervention, comparison, outcomes) format sans comparisons. The latest search was performed on June 19, 2017 supplemented with ongoing alerts from the databases when new studies within the search matrix were published (Table 1). We ended inclusion on March 31, 2018.

We included studies published in English from 1995 and onward. The temporal limitation was chosen to coincide with the development of the PAID instrument in 1995. Gray literature and reference lists of included studies were screened. Reference lists of reviews and meta-analyses retrieved from the searches were also screened. We screened the search results in Covidence Systematic Review Software.

Identification of relevant studies
The first and last authors (ASM, TT) independently screened titles and abstracts for eligibility using the following order of importance: RCT, T2DM, DD measured by DDS or PAID, and vulnerable population. Thus, the first “no” was stated as reason for exclusion. We were not masked to authors or journals during the screening process.

Data extraction and management
Characteristics of the included studies were individually extracted by ASM and GK and included the following: author, title, and year published; Methods: design including number of trial groups, country, and publication date; Participants: number at baseline and follow-up, vulnerability criteria, mean age, mean duration of T2DM, type of treatment (lifestyle, tablets, insulin), comorbidity, and diabetes-related complications. Intervention: setting, intensity, delivery, deliverer involved and training/quality control.

Risk of bias in individual studies
ASM, GK, and TT independently assessed risk of bias in included studies using the Cochrane Collaboration’s Risk of Bias Tool. Due to the nature of the intervention, blinding of participants and staff was not considered feasible. We considered DD, HRQOL, and depression at high risk of detection bias due to lack of blinding, whereas HbA1c was considered at low risk. Disagreements were discussed.
among authors until consensus was reached. We attempted to retrieve protocols in clinicaltrials.gov or published protocols for all included studies to assess potential selective reporting. In studies with missing information, the authors were contacted.

Data analysis
Meta-analyses were performed using available case analysis and the fixed or random effects method as appropriate. The meta-analyses were pairwise and were weighted by the inverse variance. We assessed the degree of heterogeneity using the $I^2$ statistic which measures the percentage of variability in effect estimates due to heterogeneity rather than sampling error. If $I^2 > 60\%$, we used the random effects method. We used the Mean Difference (MD) with 95% CI to assess effects of interventions on continuous outcomes. If different instruments were used, we used the Standardized Mean Difference (SMD). On DD and HbA1c, between-groups differences at 3, 6, 12, and 24 months follow-up were extracted. On depression and HRQOL, between-groups differences at longest follow-up were used. To increase transparency, risk of bias ratings and meta-analyses were displayed together. We investigated the risk of publication bias using funnel plots, and data analysis was conducted with Review Manager 5.3.

Subgroup analysis
The subgroup analyses are moderator analyses that explore effect heterogeneity. Results from subgroup analyses should therefore be interpreted cautiously. The following exploratory subgroup analyses were planned: 1) effect of brief (≤4 sessions) vs intensive (>4 sessions) interventions, 2) group vs individual interventions, and 3) motivational interviewing vs other interventions, all on DD and HbA1c at the longest follow-up. The exponential increase in diabetes-related health care expenditures makes it relevant to investigate the effect of less time-consuming interventions such as brief and group interventions.

Motivational interviewing may potentially be associated with greater reductions in DD and HbA1c than interventions not including motivational interviewing in people with both type 1 and type 2 diabetes. It is relevant to explore whether this is also the case when focusing specifically on vulnerable people with T2DM.

Sensitivity analysis
We planned to do two sensitivity analyses of the robustness of the effect estimate for the primary outcome DD: 1) excluding studies with high risk of bias (minimum one high risk of bias rating) and 2) excluding studies with high attrition (≥20%).

Quality of evidence
We assessed the overall quality of the evidence for the primary outcome DD and the secondary outcomes HbA1c, depression, and HRQOL using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE). This involved consideration of risk of bias, indirectness, inconsistency, imprecision, and publication bias. The quality of the evidence was rated as high, moderate, low, or very low. Two authors, ASM and TT, evaluated the quality of the evidence using GRADEpro GDT. Potential disagreements were solved by an arbiter (IE or TJ).

Results
The search yielded 5,035 potentially relevant studies. Of these, 4,721 were obviously irrelevant, leaving 314 studies that were retrieved for full-text assessment. In total, 18 RCTs involving initial recruitment of 4,066 participants were included. Thirteen studies were protocols for “ongoing studies”. Studies were primarily excluded due to not measuring DD, wrong design or intervention (Figure 1).

Characteristics of included studies
Sample sizes ranged from 47 to 623. Sixteen studies originated from the United States with a concentration of studies from deprived areas in Detroit and Boston. One study was conducted in Germany and one in India. Hospital settings were represented in 5 studies and community settings in 13. The studies were published in 2004–2017. Participants were primarily from socioeconomically deprived inner-city areas. Nine studies uniquely included patients from Hispanic, or Hawaiian or Samoan origin. In the remaining studies, participants fulfilled our vulnerability criteria primarily due to a high degree of obesity, comorbidity, and/or low educational level (Table 2). At baseline, mean age was 56±4 and mean duration of T2DM was 11±2.5 years. DD was measured with DDS in two studies and with PAID in 16 studies. Baseline mean DD measured by the 20-item PAID scale was 39±10.8. The five-item short version of PAID was used in three studies. Mean HbA1c at baseline was 8.7% (72±7.7 mmol/mol).

Interventions
The interventions included combined cognition- and emotion-focused interventions: social support, primarily support groups, some with culturally sensitive elements in
Reducing diabetes distress in vulnerable people with type 2 diabetes

Combination with decision support tools, 42 conversation maps, 51,43 coaching, 55 coping skills training and stress management, 49,53 empowerment training 47,56 and social and psychological training. 46 One study provided a telephone intervention for both the person with T2DM and spouse addressing diabetes-related conflict management with collaborative problem-solving techniques. 54 Another study involved a family member in supporting the patient using the SMART (Specific, Measurable, Attainable, Relevant and Time-bound) goal approach for behavior change with regard to healthy eating, physical activity, and management of diabetes-related distress. 50 All interventions included elements of diabetes self-management education of varying intensity. 52,57

**Standard care intervention**

Eleven studies provided enhanced standard care of varying intensity. One study sent a monthly reminder via postcard for 3 months, 40 one sent a monthly report on diabetes goals and status. 52 Four studies provided two diabetes self-management education sessions lasting 75 minutes by telephone, 44 one 2-hour or four 1-hour group sessions. 45,49,57 One study provided a 90-minute introduction to a print version of a web decision support tool and two follow-up telephone calls, 42 one offered free lab tests and consultations, 47 telephone contact every second week, 44 another delivered ten diabetes education group sessions or ten biweekly sessions of 90 minutes duration focusing on acquisition of standardized diabetes knowledge. 46 Five studies delivered standard treatment, described as general information on diabetes management provided by a health care professional every 3–4 months. Three studies had a wait-list control design, 43,50,55 and three studies delivered an intervention to all participants prior to randomization. These interventions entailed two telephone calls of 75 minutes.

---

**Figure 1 PRISMA.**

Table 2 Characteristics of included studies

<table>
<thead>
<tr>
<th>Author, year, country</th>
<th>Total (n)</th>
<th>Attrition at final follow-up (%)</th>
<th>HbA1c (mmol/mol) at baseline</th>
<th>Diabetes distress, baseline (Scale)</th>
<th>Vulnerability criteria</th>
<th>Duration, T2DM (years)</th>
<th>Mean Age</th>
<th>Intervention</th>
<th>Standard care</th>
<th>Outcomes</th>
<th>Follow-up time point (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anderson et al, 2009, USA</td>
<td>310</td>
<td>20</td>
<td>7.6% (60)</td>
<td>28 (PAiD)</td>
<td>Low socioeconomic African American (AA) BMI 34</td>
<td>8</td>
<td>56</td>
<td>One monthly phone call from DSM consultant</td>
<td>Mailed reports on diabetes status</td>
<td>HbA1c, PAID, PHQ-9</td>
<td>24</td>
</tr>
<tr>
<td>Beverly et al, 2013, USA</td>
<td>134</td>
<td>10</td>
<td>8.4% (68)</td>
<td>34 (PAiD)</td>
<td>Low socioeconomic black women</td>
<td>13</td>
<td>59</td>
<td>Conversation map group sessions</td>
<td>Sessions focusing on DSME</td>
<td>HbA1c, PAID, DQOL</td>
<td>3, 6, 12</td>
</tr>
<tr>
<td>D’Eramo et al, 2010, USA</td>
<td>109</td>
<td>28</td>
<td>8.2% (66)</td>
<td>57 (PAiD)</td>
<td>Low socioeconomic deprived</td>
<td>NR</td>
<td>48</td>
<td>Coping skill training group sessions</td>
<td>Ten 2-hour group sessions providing DSME</td>
<td>HbA1c, PAID, SF36</td>
<td>12</td>
</tr>
<tr>
<td>Gabbay et al, 2013, USA</td>
<td>545</td>
<td>23</td>
<td>9.0% (75)</td>
<td>29 (PAiD)</td>
<td>Socioeconomic deprived</td>
<td>NR</td>
<td>58</td>
<td>Individual sessions with nurse trained in MI</td>
<td>Usual care</td>
<td>HbA1c, PAID, C-DES</td>
<td>24</td>
</tr>
<tr>
<td>Heisler et al, 2014, USA</td>
<td>188</td>
<td>6</td>
<td>8.2% (66)</td>
<td>35 (PAiD)</td>
<td>Low income Latino and AA</td>
<td>9</td>
<td>NR</td>
<td>Idecide web decision support tool. Skill training, social and psychological support</td>
<td>Idecide print version</td>
<td>HbA1c and PAID</td>
<td>3</td>
</tr>
<tr>
<td>Hermanns et al, 2012, Germany</td>
<td>186</td>
<td>10</td>
<td>8.3% (67)</td>
<td>51 (PAiD)</td>
<td>Comorbidity</td>
<td>14</td>
<td>63</td>
<td>Social support group sessions</td>
<td>Sessions focusing on DSME</td>
<td>HbA1c, PAID, SF12</td>
<td>6</td>
</tr>
<tr>
<td>Ing et al, 2016, USA</td>
<td>47</td>
<td>24</td>
<td>10.0% (86)</td>
<td>34 (PAiD)</td>
<td>Hawaiian, Samoan BMI 36</td>
<td>NR</td>
<td>55</td>
<td>Empowerment app for patients</td>
<td>Postcard reminder</td>
<td>HbA1c and PAID</td>
<td>6</td>
</tr>
<tr>
<td>Kleinman et al, 2017, India</td>
<td>91</td>
<td>25</td>
<td>9.3% (78)</td>
<td>10 (PAID short)</td>
<td>Low educational level</td>
<td>NR</td>
<td>48</td>
<td>Free consultations and lab tests</td>
<td>Waiting list</td>
<td>HbA1c, PAID</td>
<td>3, 6</td>
</tr>
<tr>
<td>McEwen et al, 2017, USA</td>
<td>157</td>
<td>1</td>
<td>10.0% (86)</td>
<td>14 (DDS)</td>
<td>Mexican American adults BMI 33</td>
<td>12</td>
<td>54</td>
<td>Dyad of patient with supportive family member</td>
<td>Web training</td>
<td>HbA1c and DDS</td>
<td>6, 9</td>
</tr>
<tr>
<td>McMahon et al, 2012, USA</td>
<td>101</td>
<td>1</td>
<td>9.6% (81)</td>
<td>26 (PAID)</td>
<td>Veteran Affairs Department, BMI 34</td>
<td>NR</td>
<td>60</td>
<td>Online care group</td>
<td>Web training</td>
<td>HbA1c and PAID</td>
<td>12</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Author, year, country</th>
<th>Total (n)</th>
<th>Attrition at final follow-up (%)</th>
<th>HbA1c (mmol/mol) at baseline</th>
<th>Diabetes distress, baseline (Scale)</th>
<th>Vulnerability criteria</th>
<th>Duration, T2DM (years)</th>
<th>Mean Age</th>
<th>Intervention</th>
<th>Standard care</th>
<th>Outcomes</th>
<th>Follow-up time point (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spencer et al, 2011, USA</td>
<td>164</td>
<td>18</td>
<td>8.6% (70)</td>
<td>13 PAiD at log scale</td>
<td>Low income, AA and Latino</td>
<td>8</td>
<td>53</td>
<td>Culturally tailored group intervention</td>
<td>Delayed control group</td>
<td>HbA1c and PAiD</td>
<td>6</td>
</tr>
<tr>
<td>Sperl-Hillen et al, 2013, USA</td>
<td>623</td>
<td>0 (ITT)</td>
<td>8.3% (67)</td>
<td>30 (PAiD)</td>
<td>Low educational status</td>
<td>NR</td>
<td>NR</td>
<td>Conversation map</td>
<td>Standard care</td>
<td>HbA1c, PAID, and PHQ-9</td>
<td>12</td>
</tr>
<tr>
<td>Tang et al, 2013, USA</td>
<td>382</td>
<td>0 (ITT)</td>
<td>9.3% (78)</td>
<td>NR</td>
<td>Comorbidity</td>
<td>NR</td>
<td>54</td>
<td>MI web-based intervention</td>
<td>Standard care</td>
<td>HbA1c, DDS and PHQ-9</td>
<td>6</td>
</tr>
<tr>
<td>Trief et al, 2016, USA</td>
<td>186</td>
<td>0 (ITT)</td>
<td>9.1% (76)</td>
<td>2.3 (DDS)</td>
<td>Low income, AA and Latino</td>
<td>12</td>
<td>57</td>
<td>Couples calls</td>
<td>Diabetes education</td>
<td>HbA1c, PAID</td>
<td>4, 8, 12</td>
</tr>
<tr>
<td>Wagner et al, 2016, USA</td>
<td>107</td>
<td>23</td>
<td>8.5% (69)</td>
<td>6.5 (PAID short)</td>
<td>Deprived Latino population. 85% &lt; high school</td>
<td>NR</td>
<td>60</td>
<td>Eight CHW Diabetes education + stress management</td>
<td>One 2½ hours group session diabetes education</td>
<td>Usual care</td>
<td>3</td>
</tr>
<tr>
<td>Welch et al, 2015, USA</td>
<td>399</td>
<td>12</td>
<td>9.0% (75)</td>
<td>59 vs 51.9 control (PAID)</td>
<td>Comorbidity</td>
<td>NR</td>
<td>55</td>
<td>Clinician used dashboards + educational content + peer support groups</td>
<td>Six nurse coaching visits</td>
<td>Waitlist group design</td>
<td>6</td>
</tr>
<tr>
<td>Whittemore et al, 2004, USA</td>
<td>53</td>
<td>8</td>
<td>7.7% (61)</td>
<td>42.3 control vs 59.9 (PAID)</td>
<td>Low socioeconomic status</td>
<td>NR</td>
<td>58</td>
<td>Waitlist group design</td>
<td>HbA1c, PAID</td>
<td>HbA1c, PAID</td>
<td>3, 6</td>
</tr>
<tr>
<td>Welch et al, 2011, USA</td>
<td>234</td>
<td>22</td>
<td>8.9% (74)</td>
<td>42 (PAID)</td>
<td>BMI 36</td>
<td>NR</td>
<td>56</td>
<td>Four 30–60 minute visits DSME + MI</td>
<td>HbA1c and PAID</td>
<td>HbA1c and PAID</td>
<td>6</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CHW, certified health worker; DSM, diabetes self-management; DSME, diabetes self-management education; DQOL, Diabetes Quality of Life; MI, motivational interviewing; NR, not reported; PAiD, Problem Areas in Diabetes; PHQ, Patient Health Questionnaire.
duration, or 2.5-hour diabetes education group sessions, or 12 one-hour weekly group meetings.

**Deliverers**
The interventions were delivered by community health workers ethnically matched to patients, nurse case managers, certified diabetes educators in combination with a spouse or family member, nurses and dieticians smartphone applications combined with support from health care providers, web/telephone, or telephone. In five studies, the deliverers were trained in motivational interviewing. The training, fidelity, and quality assessment of delivery were most comprehensively described in interventions using motivational interviewing. In these studies, initial training ranged from 2 days to 80 hours with ongoing supervision of fidelity by use of validated instruments such as the Behavior Change Counseling Index or the Motivational Interviewing Skills Code.

**Risk of bias**
We chose to pool all studies in the meta-analysis and provide a narrative description of risk of bias. We judged this approach to be sound as no studies were judged at high risk of selection bias. Moreover, we performed a sensitivity analysis excluding all studies with at least one high risk of bias rating within the remaining domains in the Cochrane Collaboration’s risk of bias tool (performance bias, detection bias, attrition bias, reporting bias, and other bias).

Most studies reported sufficient data on random sequence generation and allocation concealment. Gabbay et al. moved participants not receiving the intervention to the control group after randomization, resulting in an assessment of high risk of bias. Studies providing comparable enhanced care for control group patients were judged at low risk of performance bias. Blinding of outcome assessors was explicitly reported in eight studies and insufficiently described in ten. We judged that insufficient blinding affected self-reported outcomes only. Most studies had inconsistencies between protocol and reported results, for example, insufficient information, nonreporting of specific outcomes due to nonsignificant results. Eight authors were contacted for missing information and one responded. Funnel plots were inconclusive due to less than 10 studies in each assessed outcome. Depression was a secondary outcome in all 18 studies; 16 of these reported complete results on DD. Tang et al. reported no significant effect on depression. Sperl-Hillen et al. did not report results on depression at 3, 12, and 24 months; two at 3 and 6 months; two at 6 and 12 months; and the remaining studies had one follow-up time point.

Meta-analysis of 18 studies showed no significant effect of interventions on HbA1c at any time of follow-up: MD $-0.17$ (95% CI $-0.41$, $0.06)$, $P=0.14$ at 3 months in six studies (low quality evidence; Figure 3; Supplementary material S2); MD $-0.20$ (95% CI $-0.62$, $0.05)$, $P=0.09$ at 6 months in nine studies (very low quality evidence); and the remaining studies had one follow-up time point.

**HbA1c**
HbA1c was the primary outcome in 16 studies and a secondary outcome in two studies. One study had follow-up at 3, 6, and 12 months; two at 3 and 6 months; two at 6 and 12 months; and the remaining studies had one follow-up time point.

Meta-analysis of 18 studies showed no significant effect of interventions on HbA1c at any time of follow-up: MD $-0.17$ (95% CI $-0.41$, $0.06)$, $P=0.14$ at 3 months in six studies (low quality evidence; Figure 3; Supplementary material S2); MD $-0.20$ (95% CI $-0.62$, $0.05)$, $P=0.09$ at 6 months in nine studies (very low quality evidence); and the remaining studies had one follow-up time point.

**Depression**
Depression was a secondary outcome in six studies. Gabbay et al. used the Center for Epidemiologic Studies Depression Scale; five studies used the PHQ-9 scale. Four studies reported results on depression at 3, 12, and 24 months. Tang et al. merely reported that there was no significant effect on depression. Sperl-Hillen et al. did not provide results that allow mean + SD to be calculated. Meta-analysis of four studies showed an SMD $-0.20$ (95% CI $-0.33$, $-0.07)$, $P=0.003$ (forest plot not shown) in favor of the intervention at a mean of 16±10.2 months of follow-up.
The quality of evidence was low due to serious risk of bias (summary of findings table not shown). The quality of evidence was low due to serious risk of bias and imprecision (summary of findings table not shown).

**Health-related quality of life**

HRQOL was a secondary outcome in four studies.35,46-51 Beverly et al measured HRQOL with diabetes QOL at 12 months follow-up,45 and Hermanns et al measured HRQOL with SF-12 mental score at 6 months follow-up.46 Gabbay et al did not report results due to nonsignificance,51 while D’Eramo Melkus et al reported on selected subscales of QOL only.53 Meta-analysis of the two studies reporting results on HRQOL showed an SMD of −0.09 (95% CI −0.32, 0.14), P=0.46 in favor of the intervention at a mean follow-up of 9 months (forest plot not shown). The quality of evidence was low due to serious risk of bias and imprecision (summary of findings table not shown).

**Subgroup analysis on DD**

Subgroup analysis of studies according to intervention intensity showed a significant reduction in DD of both intensive and brief interventions with the most pronounced effect after intensive intervention; intensive intervention SMD −0.20 (95% CI −0.29, −0.11), P<0.001 and brief intervention SMD −0.17 (95% CI −0.32, −0.03), P=0.02. Subgroup analysis of studies according to individual vs group interventions showed a significant reduction in DD of both individual and group interventions with the most pronounced effect after individual
Mathiesen et al. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12

### Table 3: Meta-analysis: intervention vs standard care on HbA1c at 3, 6, 12, and 24 months follow-up

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intervention Mean (SD Total)</th>
<th>Standard care Mean (SD Total)</th>
<th>Weight</th>
<th>Mean difference (95% CI)</th>
<th>Heterogeneity:</th>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2.1 HbA1c at 3 months follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heisler, 2014</td>
<td>7.8 (1.7) 87</td>
<td>7.9 (1.9) 89</td>
<td>19.1%</td>
<td>-0.10 (-0.63, 0.43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ing 2016</td>
<td>9.3 (1.8) 22</td>
<td>9.4 (2.7) 12</td>
<td>1.9%</td>
<td>-0.10 (-1.80, 1.60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kleinman 2017</td>
<td>7.9 (1.2) 44</td>
<td>8.2 (1.5) 46</td>
<td>17.3%</td>
<td>-0.30 (-0.86, 0.26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trief, 2016</td>
<td>8.3 (1.4) 97</td>
<td>8.7 (1.5) 78</td>
<td>28.7%</td>
<td>-0.40 (-0.83, 0.03)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wagner 2016</td>
<td>8.6 (1.9) 70</td>
<td>8.4 (1.6) 68</td>
<td>15.8%</td>
<td>0.20 (-0.39, 0.79)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whittemore 2004</td>
<td>7.3 (1.1) 25</td>
<td>7.4 (1.1) 24</td>
<td>17.3%</td>
<td>-0.10 (-0.66, 0.46)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>345</td>
<td>317</td>
<td>100.0%</td>
<td>-0.17 (-0.41, 0.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=1.46 (P=0.14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2.2 HbA1c at 6 months follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hermans 2011</td>
<td>7.9 (1.2) 85</td>
<td>7.8 (1.5) 82</td>
<td>11.9%</td>
<td>0.10 (-0.31, 0.51)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kleinman 2017</td>
<td>7.9 (1.1) 44</td>
<td>8.2 (1.5) 46</td>
<td>10.6%</td>
<td>-0.30 (-0.84, 0.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McEwen 2017</td>
<td>8.9 (1.8) 58</td>
<td>9.5 (1.9) 54</td>
<td>9.1%</td>
<td>-0.60 (-1.29, 0.09)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spencer 2011 (1)</td>
<td>7.9 (1.9) 56</td>
<td>8.5 (2.3) 57</td>
<td>8.2%</td>
<td>-0.70 (-1.48, 0.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tang 2013</td>
<td>7.9 (1.3) 193</td>
<td>8.6 (1.9) 189</td>
<td>12.7%</td>
<td>-0.70 (-1.04, -0.36)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trief, 2016 (2)</td>
<td>8.5 (1.5) 97</td>
<td>8.7 (1.4) 78</td>
<td>11.7%</td>
<td>-0.20 (-0.63, 0.23)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welch 2011a (3)</td>
<td>8.6 (1.35) 90</td>
<td>8.1 (1.29) 94</td>
<td>12.2%</td>
<td>0.50 (0.12, 0.88)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welch 2015 (4)</td>
<td>8.4 (1.4) 200</td>
<td>9.2 (1.4) 199</td>
<td>13.3%</td>
<td>-0.80 (-1.07, -0.53)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whittemore 2004</td>
<td>7.5 (1.1) 25</td>
<td>7.5 (1.1) 24</td>
<td>10.4%</td>
<td>0.00 (-0.56, 0.56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>848</td>
<td></td>
<td></td>
<td>-0.29 (-0.62, 0.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Z=0.20; χ²=41.27, df=8 (P=0.0001); I²=81%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=1.68 (P=0.09)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2.3 HbA1c at 12 months follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beverly 2013 (5)</td>
<td>8.54 (1.4) 58</td>
<td>8.1 (1) 63</td>
<td>14.7%</td>
<td>0.04 (0.00, 0.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D’Eramo 2010</td>
<td>7.2 (2.2) 40</td>
<td>8 (2.4) 37</td>
<td>3.3%</td>
<td>-0.80 (-1.83, 0.23)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McEwen 2017 (6)</td>
<td>9.2 (2.1) 56</td>
<td>9.2 (2) 50</td>
<td>5.6%</td>
<td>0.00 (-0.78, 0.78)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McMahon 2012</td>
<td>8.3 (1.1) 51</td>
<td>8.4 (1.7) 49</td>
<td>9.8%</td>
<td>-0.10 (-0.66, 0.46)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spen-Hillen 2013 (7)</td>
<td>7.8 (1.2) 489</td>
<td>7.7 (1.2) 134</td>
<td>31.8%</td>
<td>0.10 (-0.13, 0.33)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tang 2013</td>
<td>8.1 (1.6) 186</td>
<td>8.3 (1.8) 193</td>
<td>19.9%</td>
<td>-0.20 (-0.55, 0.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trief, 2016 (8)</td>
<td>8.5 (1.5) 97</td>
<td>8.5 (1.4) 78</td>
<td>15.0%</td>
<td>0.00 (-0.43, 0.43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>977</td>
<td>604</td>
<td>100.0%</td>
<td>0.02 (-0.17, 0.21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Z=0.02; χ²=8.10, df=6 (P=0.023); I²=28%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.20 (P=0.84)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2.4 HbA1c at 24 months follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anderson 2009</td>
<td>7.62 (1.8) 122</td>
<td>7.91 (2.03) 126</td>
<td>33.1%</td>
<td>-0.29 (-0.77, 0.19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gabbay 2013</td>
<td>7.8 (1.7) 188</td>
<td>8 (1.8) 233</td>
<td>66.9%</td>
<td>-0.20 (-0.54, 0.14)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>310</td>
<td>359</td>
<td>100.0%</td>
<td>-0.23 (-0.50, 0.04)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Z=0.00; χ²=0.09, df=1 (P=0.76); I²=0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=1.64 (P=0.10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3** Meta-analysis: intervention vs standard care on HbA1c at 3, 6, 12, and 24 months follow-up. (I) SDs calculated from CI using Revman 5.3; (II) At 8 months follow-up (ITT); (III) Mean difference calculated from within group differences; (IV) SDs calculated from SE using Revman 5.3; (V) Means+SDs from Cochran review (Chew et al. 2017); (VI) At 9 months follow-up; (VII) SDs calculated from SE using Revman 5.3; (VIII) Means+SDs from Cochran review (Chew et al. 2017); (IX) ITT: Risk of bias legend; (A) Random sequence generation (selection bias); (B) Allocation concealment (selection bias); (C) Blinding of participants and personnel (performance bias); (D) Blinding of outcome assessment (detection bias); (E) Incomplete outcome data (attrition bias); (F) Selective reporting (reporting bias); (G) Other bias.

**Intervention** vs **Standard care**: SMD −0.25 (95% CI −0.36, −0.14), P<0.001 vs SMD −0.13 (−0.24, −0.02), P=0.02. Subgroup analysis of the three studies incorporating motivational interviewing showed a significant reduction in favor of motivational interviewing; SMD −0.25 (95% CI −0.39, −0.10), P=0.001 (Supplementary material S3; subgroup analyses DD).

**Subgroup analysis on HbA1c**

Meta-analysis of studies according to intervention intensity showed a reduction in HbA1c after intensive interventions, but deterioration after brief interventions; M= −0.23 (95% CI −0.44, −0.01), P=0.04 and M= 0.15 (95% CI −0.11, 0.40), P=0.26, respectively. Meta-analysis of studies according to individual vs group showed a reduction in HbA1c of individual, but not group intervention; M= −0.15 (95% CI −0.45, 0.15), P=0.34 and M= 0.02 (95% CI −0.18, 0.21), P=0.86, respectively. Meta-analysis of studies according to use of motivational interviewing showed a reduction of −0.08 (95% CI −0.43, 0.26), P=0.63 in favor of motivational interviewing (Supplementary material S4).

**Sensitivity analysis**

Removing six studies at high risk of attrition bias did not significantly change estimates of intervention effects on DD: SMD −0.25 (95% CI −0.55, 0.04) P=0.09 at 3 months, SMD −0.19 (95% CI −0.31, −0.08) P=0.01 at 6 months, and
at 12 months, SMD −0.19 (95% CI −0.32, −0.06) P=0.005. Removing studies with at least one high risk of bias rating reduced effect estimates at 6 months, SMD −0.15 (95% CI −0.33, 0.03) P=0.10 and at 24 months, SMD −0.14 (95% CI −0.39, 0.11) P=0.28, while the effect estimates increased at 3 months, SMD −0.26 (95% CI −0.44, 0.07) P=0.007 and at 12 months, SMD −0.23 (95% CI −0.38, −0.09) P=0.002.

**Discussion**

This review provided low to moderate quality evidence for small significant reductions in DD over time and very low to moderate quality evidence for no effect on HbA1c of psychosocial interventions. We found low quality evidence for a small reduction in depression, and moderate quality evidence for no effect on HRQOL.

The effect on DD was small (SMD <0.40);25 nevertheless, it may reflect a clinically significant improvement in a high-risk population disproportionately affected by a clustering of risk factors and ensuing high risk of diabetes complications.5,20 The most distressed persons are also more likely to have high blood pressure46 and high LDL cholesterol,3 both factors equally important as HbA1c for prevention of micro- and macrovascular complications.61 There is evidence for an association between DD and adherence to medication.5,18

Reducing DD and thereby increasing treatment adherence might be an intermediate pathway to preventing diabetes complications in this population. In a review also focusing on cognition- and emotion-focused interventions, Chew et al reported nonsignificant reductions in DD in a general population with T2DM.20 Our findings indicate that vulnerable people with T2DM might benefit proportionately more from psychosocial interventions targeting DD.

The reduction in DD was not accompanied by a reduction in HbA1c. This opposed to Fisher et al.12 who reported a significant association between reduced DD and improved glycemic control during 18 months follow-up in a general T2DM population. Chew et al. reported a borderline significant effect on HbA1c, but as previously mentioned, no effect on DD.20

The conflicting findings might be explained by the vulnerability criteria applied in this review including one or more comorbidities62 and longer duration of diabetes23 which, pathophysiologically63 and mentally, might hamper possible effects of interventions on HbA1c despite reduced levels of DD. From an equity perspective, people with low socioeconomic status, low health literacy, and diabetes-related sequelae may profit less from interventions, in spite of efforts to tailor interventions to their particular needs.64 Hypothetically, not all interventions in included studies were optimally customized to this specific population. Furthermore, vulnerability may affect adherence to interventions in clinical trials.65 An implication of our findings could be stratified interventions for patients with low health literacy, social problems, and language and logistic barriers. This could accommodate access, attendance, and integration of interventions and potentially reduce attrition in this group of patients. Stratified interventions would likely require training of health care professionals in culturally and literacy sensitive aspects of person-centered diabetes care.

The lacking effect on HbA1c lends support to previous research suggesting a noncausal link between DD and HbA1c.13 However, provision of preintervention to all participants prior to randomization in three studies40,49,54 and enhanced standard care to control groups in eleven studies40,42,44,47,49,52–54,58 might also have played a role. Previous trials have moreover suggested that behavioral interventions may be more effective in people with a poorer baseline psychological state,66 while other studies link their effectiveness to having intervened on people with HbA1c ≥9.0% (75 mmol/mol).67 Indeed, the baseline levels of both DD (mean 39±10.8) and HbA1c 8.7% (mean 72±7.7) were clinically important in the studies included.68 Preinterventions and enhanced standard care may, however, have weakened the level to which DD and HbA1c could be reduced. This explanation is supported by the weaker effect of interventions at 3 months compared with 6 months contradictory to the well-established Hawthorne effect.69

There was low quality evidence from four studies for a small but significant reduction in depression. This lends support to the suggested link between depression and DD9 and may have clinical potential if there is an association between reduced depression and improved diabetes self-management, as previously reported.18 Our results may, however, reflect the instruments used to measure depression in included studies. According to Fisher et al, depression should be assessed using a gold standard structured clinical interview.11 Preferably, this approach should be used uniformly to distinguish depression from DD and direct care effectively.11 Despite the heterogeneous instruments used, studies have reported a disproportionate burden of depression in people with T2DM.70 Similar to our findings, other studies also failed to identify improvements in glycemic control despite reduction in depression.13,71

Exploratory subgroup analysis indicated a deteriorating effect of brief interventions on HbA1c. This could indicate that vulnerable people with T2DM benefit less from brief
interventions, perhaps because they lack individualized peer support.72 This points toward a need for continuity and a designated health care professional as proposed in other studies.73,74 The explorative subgroup analyses of effects on DD of individual vs group and intensive vs brief interventions endorse this interpretation.

Subgroup analysis of interventions incorporating motivational interviewing indicated a potential association with reduced DD. Again, this effect did not “spill over” on HbA1c, although it should be noted that only one of the studies included in the analysis identified an increase in HbA1c.57 This study tested a brief intervention and was at high risk of bias, primarily due to attrition (35%).57

Our results lend support to the relevance of further research on person-centered care such as motivational interviewing for reducing DD, and increasing glycemic control in vulnerable people with T2DM.21 Diverse theoretical foundations determined the content of interventions. Notwithstanding the value of theoretically founded interventions, there is some concern about a potential gap between theory and the implementation of person-centered care in clinical practice.75 If interventions do not sufficiently reflect the theoretical foundation, effect may be weakened. Our review nevertheless adds further to the potential promise of person-centered care, eg, motivational interviewing including person-centered support from a devoted person for vulnerable people with T2D.

Such approaches should consider the patients’ everyday life including their social network and life values.

Strengths and limitations

This review adhered to the Cochrane Collaboration’s methodology for systematic reviews to rigorously examine the evidence for an effect of psychosocial interventions vs standard care on DD and, secondly, on HbA1c, depression, and HRQOL in vulnerable people with T2DM. Nonetheless, several factors might have influenced effect estimates.

We applied the SMD on outcomes where studies used different instruments for measuring DD, depression, and HRQOL. The application of the SMD has, however, been reported to be inaccurate and even erroneous79 due to data extraction errors, mistakes in calculations, or confusion regarding the direction of the included scales for specific outcomes. To avoid these pitfalls, our data extraction process was performed twice by each reviewer to ensure accuracy. Moreover, we used Review Manager to perform calculations and chose to include only studies using validated instruments (PAID and DDS).

Secondly, sensitivity analysis revealed that removing studies with high risk of bias reduced effect estimates on DD at 6 and 24 months follow-up, while they increased at 3 and 12 months. The results remained statically significant at 3 and 12 months follow-up only. This differs from the findings of Savovic et al, who concluded that low quality studies are more likely to report large effect sizes.77 Removing studies with high attrition marginally attenuated effect estimates on DD. This might indicate a minor overestimation of effect sizes due to high attrition. However, the effect on DD at 6 and 12 months remained statistically significant.

Thirdly, poor reporting of results and missing information resulted in an assessment of most studies as being at “unclear” risk of bias. Likewise, in studies with insufficient reporting, some authors stated that lack of reported results was due to nonsignificant differences between groups at follow-up.36 Consequently, studies showing no increase or decrease in outcomes were not included in meta-analyses, potentially leading to overestimation of effects. Inclusion of a wait-list design in three studies might have induced anticipation bias and reduced between-group differences at follow-up. Moreover, the use of available case analysis may have augmented the effect on all outcomes.

Baseline DD values differed significantly between the intervention and the control groups in four studies.47,48,55,44 Due to nonreporting of change scores in eleven studies41,45,47–51,53–56 and the use of different instruments for measuring DD, we considered that post hoc exploratory analyses using available change scores would be misleading.25 Moreover, imbalance between groups at baseline should be eliminated in meta-analysis.36

If the effects of emotion- vs cognition-based interventions could be distinguished, it might have strengthened the review. However, some of the most cited theoretical models underlying the interventions, eg, Bandura’s model on self-efficacy,30,31 involve both emotion- and cognition-based constructs. Therefore, we were unable to distinguish effects of interventions according to underlying theory. The generalizability of our findings might be limited by the inclusion of only two studies originating from other countries than United States.

Conclusion

We found low to moderate quality evidence for a significant, but small reduction in DD and very low to moderate quality evidence for no effect on HbA1c at 3, 6, 12, and 24 months follow-up of psychosocial interventions. The reduction in depression was significant, but small, while there was no effect on HRQOL. Exploratory subgroup analyses showed significant incremental reductions in DD and HbA1c of intensive (>4 sessions) vs brief interventions. On HbA1c, there was a nonsignificant trend toward deteriorating HbA1c.
after brief intervention. Individual and group interventions significantly reduced DD, but not HbA1c. On both outcomes the largest reductions were found after individual interventions. Subgroup analysis of interventions using motivational interviewing was associated with larger effects on DD, but not on HbA1c.

Acknowledgments
This review was funded by the University Hospital of Copenhagen, Rigshospitalet, grant number E-22260-04, Denmark, TRYG Foundation, Denmark, Grant number 103925, The Novo Nordisk Foundation, Denmark, Grant Number 6265, and the Lundbeck Foundation, Denmark. The funding sources had no role in any stage of the research process.

Author contributions
Literature searches were performed by ASM. The initial screening of title and abstract, including full-text screening, was performed by ASM and TT. Data from studies eligible for inclusion were extracted and bias assessed by ASM and GK with disagreement solved by IE or TT. Meta-analyses and GRADE assessments were conducted by ASM and TT. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


